EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of a relapsed radio- and chemotherapy refractory primary CNS lymphoma with the anti-CD-20 antibody IDEC-C2B8



Treatment of a relapsed radio- and chemotherapy refractory primary CNS lymphoma with the anti-CD-20 antibody IDEC-C2B8



Neurology 56(8 Supplement 3): A411, April 24




(PDF 0-2 workdays service: $29.90)

Accession: 035980688

Download citation: RISBibTeXText



Related references

Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. Annals of Oncology 9(5): 527-534, 1998

Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody. International Journal of Hematology 74(1): 70-75, 2001

IDEC-C2B8 chimeric anti-CD20 antibody Safety and clinical activity in the treatment of patients with relapsed low-grade or follicular non-Hodgkins lymphoma. British Journal of Haematology 93(SUPPL 2): 283, 1996

Pharmacokinetics and pharmacodynamics of the anti-CD20 antibody IDEC-C2B8 in patients with relapsed low-grade or follicular lymphoma. Blood 88(10 SUPPL 1 PART 1-2): 90A, 1996

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90(6): 2188-2195, 1997

Analysis of bcl-2 t translocation in relapsed B-cell lymphoma patients treated with the chimeric anti-CD20 antibody IDEC-C2B8. Proceedings of the American Association for Cancer Research Annual Meeting 37(0): 213, 1996

Pharmacokinetic analysis of serum concentrations of the chimeric anti-CD20 antibody IDEC-C2B8 in patients with relapsed B cell lymphoma. Proceedings of the American Association for Cancer Research Annual Meeting 36(0): 365, 1995

Pharmacokinetics of the chimeric anti-CD20 antibody IDEC-C2B8 Analysis of serum concentrations in patients with relapsed B-cell lymphoma. British Journal of Haematology 93(SUPPL 2): 283, 1996

IDEC-C2B8 anti-CD20 antibody Final report on a phase III pivotal trial in patients with relapsed low-grade or follicular lymphoma. Blood 88(10 SUPPL 1 PART 1-2): 90A, 1996

IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: Results of a phase-II study of the German Low-Grade Lymphoma Study Group. Annals of Hematology 79(9): 493-500, 2000

Anti-CD20 antibody , IDEC-C2B8 Clearance of bcl-2 t positive cells from peripheral blood and bone marrow in patients with relapsed low-grade or follicular lymphoma. Blood 88(10 SUPPL 1 PART 1-2): 91A, 1996

Phase I study of IDEC-C2B8 in patients with relapsed or refractory B-cell non-Hodgkins lymphoma in Japan. Experimental Hematology (Charlottesville) 25(8): 846, 1997

Anti-CD20 chimeric antibody, IDEC-C2B8 Safety and clinical activity in the treatment of relapsed low grade or follicular lymphomas. Experimental Hematology (Charlottesville) 24(9): 1150, 1996